Today announced the initiation of a multi-center Phase 1/2 medical trial in Japan of ponatinib.

We are working closely with these CML professionals and anticipate that trial will confirm the outcomes seen with ponatinib in our ongoing Phase 1 and pivotal Stage 2 trials of ponatinib. .. ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan ARIAD Pharmaceuticals, Inc. today announced the initiation of a multi-center Phase 1/2 medical trial in Japan of ponatinib, the Company’s investigational BCR-ABL inhibitor. The trial is being conducted in Japanese individuals with chronic myeloid leukemia who have failed treatment with dasatinib or nilotinib or with Philadelphia-chromosome positive severe lymphoblastic leukemia who’ve failed prior tyrosine kinase inhibitors.‘The pending mix of Actavis and Allergan will create a dynamic new variety of company – a innovator in Development Pharma. By adopting the Allergan name for the organization we will make sure that our corporate identity reflects the dramatic evolution of our firm within the pharmaceutical sector,’ said Brent Saunders, President and CEO of Actavis.’For more than 65 years, the Allergan name provides represented advancement in branded pharmaceuticals, a committed action to bringing the best medicine alive and a strong partnership with physicians.The Actavis name has represented our global commitment to leadership in generic, branded generic and OTC pharmaceuticals and to increased access to more affordable prescription drugs for consumers around the world.